Conducting the dynamic risk assessment in patients with differentiated thyroid cancer (DTC) during follow-up period is a newly proposed concept that is closely linked to the characteristics of the disease, and it is a critical and solid step towards individualized and precise management. The present review is to comprehensively illustrate the dynamic risk assessment of DTC from the aspects of the development process, the standpoint of the guidelines, and the follow-up recommendations according to the assessment results, as well as the limitations and prospects of the current risk stratification.